leadf
logo-loader
viewNoxopharm Ltd
(
ASX:NOX
)

Noxopharm CEO encouraged by positive interim data from NOXCOVID trial

Noxopharm Ltd (ASX:NOX) CEO and managing director Dr Graham Kelly speaks to Proactive's Andrew Scott after reporting positive interim data from its NOXCOVID trial. The interim data points to Veyonda in a cohort of 18 patients with moderately severe COVID19 disease, providing protection against progression of severe inflammation associated with a worsening of the disease.

Quick facts: Noxopharm Ltd

Follow
ASX:NOX

Price: 0.565 AUD

Market Cap: $162.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Noxopharm to expand NOXCOVID program following positive phase 1 results

Noxopharm Ltd (ASX:NOX)'s Graham Kelly tells Proactive they're planning to expand its NOXCOVID clinical program after receiving positive preliminary top-line data from its Phase 1 clinical trial for patients with coronavirus. The company's positioning Veyonda (idronoxil) as an anti-inflammatory...

on 24/8/21

2 min read